ACADIA Pharmaceuticals (ACAD) 10-K2009 FY Annual report

Filed: 9 Mar 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: adjacent, adjunctive, adjunctively, aggressive, agitation, Alzheimer, arrive, ASC, Asia, Asian, authoritative, Biovail, Canada, cell, cholinesterase, clarification, Codification, deliverable, diagnostic, disappointing, equivalent, exit, exploratory, Fanapt, Fourth, frail, frequency, host, institutionalization, Japan, Kaisha, Keisha, longest, Meija, Meiji, memory, methodology, Mexico, neurodegenerative, nighttime, nongovernmental, ourself, precognitive, prominent, Qualitative, Quantitative, rental, rest, royalty, runway, Russia, Seika, simple, slowly, SRL, streamline, Submitter, suited, Supplementary, tablet, technique, territory, troublesome, unavailable, Unified, unwanted, worse

Removed: Abbey, acid, activating, adult, agonist, alter, Ambien, amortize, analyze, androgen, anniversary, ARB, Australia, bearing, breach, breakthrough, building, Bulletin, cellular, classification, cloned, complain, computing, concentrating, construction, converted, convertible, CR, cultured, daytime, deepest, detailed, determinable, determination, effected, efficient, EITF, Emerging, enabled, energy, enroll, essentially, evaluated, exhibited, explanation, fee, fluorescence, FSP, GABA, hangover, inclusive, insomnia, interacting, interpretation, inverse, irritability, joint, kinase, King, kinsase, knowledge, latency, lethargy, library, linked, Lunesta, marker, month, neuropsychiatry, night, nominated, optimization, optionee, original, persuasive, pharmacological, pivotal, principle, reclassification, remeasured, rendered, repurchase, restorative, returning, reverse, revised, Rozerem, SAB, seed, settle, show, signal, SMRI, Sonata, split, startup, statistically, stimulate, strong, structurally, structure, suitable, Takeda, Task, testosterone, Tolf, trailing, transduction, tyrosine, unappreciated, uncertainty, Uniform, valuable, variable, wave

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ACAD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ACADIA Pharmaceuticals Inc. (the “Company”) on Form 10-K for the period ended December 31, 2009, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Thomas H. Aasen, Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge, that:

(1) the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report.

Date: March 9, 2010

/s/ THOMAS H. AASEN

Thomas H. Aasen

Vice President and

Chief Financial Officer

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liability of Section 18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.